153 related articles for article (PubMed ID: 26095919)
1. Mortalin is Expressed by Astrocytes and Decreased in the Midbrain of Parkinson's Disease Patients.
Cook TJ; Hoekstra JG; Eaton DL; Zhang J
Brain Pathol; 2016 Jan; 26(1):75-81. PubMed ID: 26095919
[TBL] [Abstract][Full Text] [Related]
2. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase.
Ishida Y; Nagai A; Kobayashi S; Kim SU
J Neuropathol Exp Neurol; 2006 Jan; 65(1):66-77. PubMed ID: 16410750
[TBL] [Abstract][Full Text] [Related]
4. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.
Neal ML; Boyle AM; Budge KM; Safadi FF; Richardson JR
J Neuroinflammation; 2018 Mar; 15(1):73. PubMed ID: 29519253
[TBL] [Abstract][Full Text] [Related]
5. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
6. Enteric GFAP expression and phosphorylation in Parkinson's disease.
Clairembault T; Kamphuis W; Leclair-Visonneau L; Rolli-Derkinderen M; Coron E; Neunlist M; Hol EM; Derkinderen P
J Neurochem; 2014 Sep; 130(6):805-15. PubMed ID: 24749759
[TBL] [Abstract][Full Text] [Related]
7. Mortalin inhibition in experimental Parkinson's disease.
Chiasserini D; Tozzi A; de Iure A; Tantucci M; Susta F; Orvietani PL; Koya K; Binaglia L; Calabresi P
Mov Disord; 2011 Aug; 26(9):1639-47. PubMed ID: 21542017
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin.
Yang H; Zhou X; Liu X; Yang L; Chen Q; Zhao D; Zuo J; Liu W
Biochem Biophys Res Commun; 2011 Jun; 410(1):114-20. PubMed ID: 21640711
[TBL] [Abstract][Full Text] [Related]
9. Gallyas-positive, tau-negative glial inclusions in Parkinson's disease midbrain.
Wakabayashi K; Takahashi H
Neurosci Lett; 1996 Oct; 217(2-3):133-6. PubMed ID: 8916090
[TBL] [Abstract][Full Text] [Related]
10. Serum Mortalin Correlated with α-Synuclein as Serum Markers in Parkinson's Disease: A Pilot Study.
Singh AP; Bajaj T; Gupta D; Singh SB; Chakrawarty A; Goyal V; Dey AB; Dey S
Neuromolecular Med; 2018 Mar; 20(1):83-89. PubMed ID: 29307058
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis.
Burbulla LF; Schelling C; Kato H; Rapaport D; Woitalla D; Schiesling C; Schulte C; Sharma M; Illig T; Bauer P; Jung S; Nordheim A; Schöls L; Riess O; Krüger R
Hum Mol Genet; 2010 Nov; 19(22):4437-52. PubMed ID: 20817635
[TBL] [Abstract][Full Text] [Related]
12. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein.
Liu FT; Chen Y; Yang YJ; Yang L; Yu M; Zhao J; Wu JJ; Huang F; Liu W; Ding ZT; Wang J
Brain Res; 2015 Apr; 1604():52-61. PubMed ID: 25665531
[TBL] [Abstract][Full Text] [Related]
13. Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease.
De Mena L; Coto E; Sánchez-Ferrero E; Ribacoba R; Guisasola LM; Salvador C; Blázquez M; Alvarez V
J Neural Transm (Vienna); 2009 Oct; 116(10):1289-93. PubMed ID: 19657588
[TBL] [Abstract][Full Text] [Related]
14. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.
Andringa G; Bol JG; Wang X; Boekel A; Bennett MC; Chase TN; Drukarch B
Neuropathol Appl Neurobiol; 2006 Apr; 32(2):157-69. PubMed ID: 16599944
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of mortalin expression in human brain tumors.
Takano S; Wadhwa R; Yoshii Y; Nose T; Kaul SC; Mitsui Y
Exp Cell Res; 1997 Nov; 237(1):38-45. PubMed ID: 9417864
[TBL] [Abstract][Full Text] [Related]
16. Mortalin: a protein associated with progression of Parkinson disease?
Shi M; Jin J; Wang Y; Beyer RP; Kitsou E; Albin RL; Gearing M; Pan C; Zhang J
J Neuropathol Exp Neurol; 2008 Feb; 67(2):117-24. PubMed ID: 18219256
[TBL] [Abstract][Full Text] [Related]
17. Mortalin mutations are not a frequent cause of early-onset Parkinson disease.
Freimann K; Zschiedrich K; Brüggemann N; Grünewald A; Pawlack H; Hagenah J; Lohmann K; Klein C; Westenberger A
Neurobiol Aging; 2013 Nov; 34(11):2694.e19-20. PubMed ID: 23831374
[TBL] [Abstract][Full Text] [Related]
18. Expression of mortalin detected in human liver cancer by tissue microarrays.
Chen X; Xu B; Li H; Yang L; Zuo J; Liu W; Liu C
Anat Rec (Hoboken); 2011 Aug; 294(8):1344-51. PubMed ID: 21714113
[TBL] [Abstract][Full Text] [Related]
19. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
20. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
